| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:3 | Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits | Nervous system disease | WPHA/WNT Endorsed | Human, Rat | 0.14 | KE:887 | Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
| AOP:4 | Ecdysone receptor agonism leading to incomplete ecdysis associated mortality | Unclassified | - | Insects, Crustaceans | 0.1 | KE:993 | Decrease, Abdominal muscle contraction |
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.2 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.11 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic disease | WPHA/WNT Endorsed | Mus musculus, Drosophila melanogaster, Oryzias latipes, Syrian golden hamster | 0.25 | KE:155 | Inadequate DNA repair |
| AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | Pimephales promelas | 0.1 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.12 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory system disease | Under Development | Human, Mouse | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | ||||||
| KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | ||||||
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.14 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
| AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.08 | KE:536 | Altered, Chromosome number (polyploid) zygote | |
| AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
| AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | Honey bee | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:96 | Axonal sodium channel modulation leading to acute mortality | Unclassified | - | Insects, Fish | 0.17 | KE:602 | Increased, Ataxia, paralysis, or hyperactivity |
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.14 | KE:341 | Impairment, Learning and memory |
| AOP:104 | Altered ion channel activity leading impaired heart function | Unclassified | - | 0.25 | KE:699 | Increased, cardiac arrthymia | |
| AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory system disease | - | Mus musculus | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:281 | Thyroxine (T4) in serum, Decreased |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:113 | Glutamate-gated chloride channel activation leading to acute mortality | Unclassified | - | Bombus impatiens, Chaetanaphothrips orchidii, Radopholus similis, Daphnia magna, Orius insidiosus, Hymenoptera, Helicoverpa zea, Lepidoptera, Liriomyza trifolii, Orius isidiosus, Acyrthosiphon kondoi | 0.17 | KE:764 | N/A, Ataxia, paralysis, or hyperactivity |
| AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | Rattus norvegicus | 0.33 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
| KE:777 | Increase, Inflammation (corneal cells) | ||||||
| AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | Mus musculus, Rattus norvegicus | 0.4 | KE:149 | Increase, Inflammation |
| KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | ||||||
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:281 | Thyroxine (T4) in serum, Decreased |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.1 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.09 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.08 | KE:536 | Altered, Chromosome number (polyploid) zygote | |
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.18 | KE:281 | Thyroxine (T4) in serum, Decreased |
| KE:825 | Decreased, Renal ability to dilute urine | ||||||
| AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign neoplasm; Respiratory system disease | Under Review | 0.14 | KE:870 | Increase, Cell Proliferation | |
| AOP:155 | Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Zebrafish | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:156 | Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:157 | Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:158 | Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.25 | KE:1003 | Decreased, Triiodothyronine (T3) |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive system disease | - | CD-1 mouse, SD rat | 0.33 | KE:1043 | Hypertrophy/hyperplasia, smooth muscle |
| KE:1042 | Proliferation/Clonal Expansion, smooth muscle | ||||||
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.14 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
| AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal system disease; Respiratory system disease | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.12 | KE:1497 | Increased, recruitment of inflammatory cells |
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:189 | Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
| AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:194 | Hepatic nuclear receptor activation leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:281 | Thyroxine (T4) in serum, Decreased |
| AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | Homo sapiens | 0.17 | KE:149 | Increase, Inflammation |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.38 | KE:1115 | Increase, Reactive oxygen species |
| KE:1281 | Increased, DNA Damage-Repair | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.17 | KE:1262 | Apoptosis |
| AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:227 | NSAID induced PTGS1 inactivation to gastric ulcer | Gastrointestinal system disease | - | 0.14 | KE:1403 | Reduced, platelet aggregation | |
| AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | Lemna minor, Lemna gibba | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:256 | Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse | 0.2 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| AOP:257 | Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse, Dog, Monkey | 0.2 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse | 0.4 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.43 | KE:155 | Inadequate DNA repair |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:276 | Inhibition of complex I of the electron transport chain leading to chemical induced Fanconi syndrome | Urinary system disease | - | 0.17 | KE:887 | Inhibition, NADH-ubiquinone oxidoreductase (complex I) | |
| AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal system disease; Respiratory system disease | - | 0.14 | KE:149 | Increase, Inflammation | |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1825 | Increase, Cell death | ||||||
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | Daphnia magna | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1825 | Increase, Cell death | ||||||
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.11 | KE:1182 | Increase, Cell Proliferation (Epithelial Cells) |
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.11 | KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |
| AOP:297 | Inhibition of retinaldehyde dehydrogenase leads to population decline | Unclassified | Under Development | Fish | 0.17 | KE:1643 | Altered, Visual function |
| AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.57 | KE:1497 | Increased, recruitment of inflammatory cells |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | Zebrafish | 0.08 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
| AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | Daphnia magna, Fish | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.09 | KE:10042 | Abnormal development | |
| AOP:334 | Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration | Unclassified | - | Teleost fish | 0.17 | KE:2245 | Altered Cell Differentiation Signaling |
| AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary system disease | - | Rat | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:337 | DNA methyltransferase inhibition leading to population decline (2) | Unclassified | - | Daphnia magna | 0.12 | KE:1776 | Increase, Ovarian somatic cell apoptosis |
| AOP:339 | DNA methyltransferase inhibition leading to population decline (4) | Unclassified | - | 0.12 | KE:1776 | Increase, Ovarian somatic cell apoptosis | |
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.2 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
| AOP:362 | Immune mediated hepatitis | Gastrointestinal system disease; Immune system disease | - | Homo sapiens, Rat | 0.12 | KE:1817 | Apoptotic cell death |
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.38 | KE:1003 | Decreased, Triiodothyronine (T3) |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:1643 | Altered, Visual function | ||||||
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.38 | KE:1003 | Decreased, Triiodothyronine (T3) | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:1643 | Altered, Visual function | ||||||
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.38 | KE:1003 | Decreased, Triiodothyronine (T3) | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:1643 | Altered, Visual function | ||||||
| AOP:366 | Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis | Unclassified | - | 0.14 | KE:281 | Thyroxine (T4) in serum, Decreased | |
| AOP:367 | Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis | Unclassified | - | 0.14 | KE:281 | Thyroxine (T4) in serum, Decreased | |
| AOP:368 | Cytochrome oxidase inhibition leading to increased nasal lesions | Unclassified | - | Rodents, Human | 0.33 | KE:1825 | Increase, Cell death |
| AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous system disease | Under Development | Human | 0.25 | KE:352 | N/A, Neurodegeneration |
| AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive system disease | - | Lemna minor, Chlamydomonas reinhardtii | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive system disease | - | Lemna minor | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| KE:40 | Decrease, Mitochondrial ATP production | ||||||
| AOP:388 | Deposition of ionising energy leading to population decline via programmed cell death | Reproductive system disease | - | Lemna minor | 0.2 | KE:1864 | Increase, Programmed cell death |
| AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | Humans | 0.2 | KE:1497 | Increased, recruitment of inflammatory cells |
| AOP:397 | Bulky DNA adducts leading to mutations | Genetic disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair | |
| AOP:398 | Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia | Reproductive system disease | Under Development | Mouse, Rat, Human | 0.17 | KE:1883 | Decreased, size of the ovarian reserve |
| AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | Zebrafish | 0.25 | KE:1821 | Decrease, Cell proliferation |
| KE:1643 | Altered, Visual function | ||||||
| AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.17 | KE:1869 | Diminished protective oxidative stress response | |
| AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.62 | KE:1115 | Increase, Reactive oxygen species | |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| KE:1896 | Genomic instability | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:410 | GSK3beta inactivation leading to increased mortality via defects in developing inner ear | Unclassified | - | Zebrafish | 0.2 | KE:1825 | Increase, Cell death |
| KE:1008 | Reduced, Hearing | ||||||
| AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | 0.2 | KE:1920 | Altered gene expression, TGF-β dependent fibrosis pathway | |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.2 | KE:1669 | Increased, DNA damage and mutation | |
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:870 | Increase, Cell Proliferation | |
| AOP:437 | Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity | Urinary system disease | Under Development | 0.2 | KE:709 | Increase, Cytotoxicity (renal tubular cell) | |
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.44 | KE:1971 | Increased, tumor growth |
| KE:149 | Increase, Inflammation | ||||||
| KE:1241 | Increased, Motility | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.14 | KE:1262 | Apoptosis |
| AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.11 | KE:1365 | Increase, Apoptosis | |
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.44 | KE:1497 | Increased, recruitment of inflammatory cells |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1669 | Increased, DNA damage and mutation | ||||||
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.22 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous system disease | - | 0.05 | KE:1825 | Increase, Cell death | |
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:2050 | Increase, developmental abnormalities | |
| AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities | |
| AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.25 | KE:1825 | Increase, Cell death | |
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous system disease; Monogenic disease | Under Review | Human, Mouse, Rat, Rhesus monkeys, Rabbit, Guinea pig | 0.3 | KE:155 | Inadequate DNA repair |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular system disease; Thoracic disease | Under Development | 0.2 | KE:40 | Decrease, Mitochondrial ATP production | |
| AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal system disease | Under Review | Human, Mouse, Rat, Rhesus monkeys | 0.29 | KE:1825 | Increase, Cell death |
| KE:2245 | Altered Cell Differentiation Signaling | ||||||
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.2 | KE:2119 | Insulin resistance, increased |
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.22 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| KE:1183 | Decreased, Apoptosis (Epithelial Cells) | ||||||
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1896 | Genomic instability |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | 0.14 | KE:1365 | Increase, Apoptosis | |
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:524 | Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals | Immune system disease; Gastrointestinal system disease | - | Human | 0.11 | KE:1931 | Intestinal barrier, disruption |
| AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous system disease | - | Homo sapiens, Mus musculus | 0.17 | KE:149 | Increase, Inflammation |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.33 | KE:1883 | Decreased, size of the ovarian reserve |
| KE:1262 | Apoptosis | ||||||
| AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | Zebrafish | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:2195 | Increase, CNS Neural cell death | ||||||
| AOP:574 | Inhibition, cytochrome oxidase leads to Loss of olfactory function | Unclassified | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | Mus musculus, Homo sapiens, Pimephales promelas, Colinus virginianus, Rattus norvegicus | 0.12 | KE:864 | Decreased, Body Weight |
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.25 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.1 | KE:341 | Impairment, Learning and memory |
| AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive system disease | - | 0.2 | KE:337 | N/A, Impairment of reproductive capacity | |
| AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Gallus gallus | 0.4 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.38 | KE:357 | Cholestasis, Pathology |
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal system disease | Under Development | Mouse, Rat | 0.4 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.4 | KE:827 | sensitisation, skin |
| KE:272 | Activation/Proliferation, T-cells | ||||||
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.25 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | Mouse, Zebrafish, Rats, Human | 0.2 | KE:1001 | Increased, Developmental Defects |
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.22 | KE:352 | N/A, Neurodegeneration |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.2 | KE:281 | Thyroxine (T4) in serum, Decreased |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.5 | KE:709 | Increase, Cytotoxicity (renal tubular cell) |
| KE:713 | Increase, Adenomas/carcinomas (renal tubular) | ||||||
| KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | ||||||
| AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal system disease | Under Review | Rattus norvegicus, Mus musculus | 0.4 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.17 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
| AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.5 | KE:713 | Increase, Adenomas/carcinomas (renal tubular) |
| KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) | ||||||
| AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | Under Development | Mus musculus, Rattus norvegicus | 0.5 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:719 | Increase, hepatocellular adenomas and carcinomas | ||||||
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.17 | KE:330 | Decrease, Fertility |
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.22 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.5 | KE:885 | Increase, Cancer |
| KE:155 | Inadequate DNA repair | ||||||
| AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory system disease | Under Development | Human, Mouse, Rat | 0.25 | KE:1250 | Decrease, Lung function |
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.1 | KE:952 | Hypertension |
| AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | Chicken, Zebrafish, Mouse, Rattus norvegicus | 0.29 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory system disease | - | 0.11 | KE:1226 | Increased Respiratory irritability and Chronic Cough, | |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.33 | KE:1263 | Necrosis |
| KE:1262 | Apoptosis | ||||||
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.6 | KE:1395 | Liver Cancer |
| KE:1393 | Hepatocytotoxicity | ||||||
| KE:1394 | Induction, persistent proliferation/sustained proliferation | ||||||
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.29 | KE:1513 | General Apoptosis |
| KE:1514 | Neurodegeneration | ||||||
| AOP:261 | L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility | Cardiovascular system disease | Under Development | Vertebrates | 0.12 | KE:1535 | Heart failure |
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development | |
| AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural tube defect | - | 0.2 | KE:1561 | Neural tube defects | |
| AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.12 | KE:1549 | Liver Injury | |
| AOP:279 | Microtubule interacting drugs lead to peripheral neuropathy | Nervous system disease | - | 0.25 | KE:1583 | Sensory axonal peripheral neuropathy | |
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.1 | KE:352 | N/A, Neurodegeneration | |
| AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic disease; Chromosomal disease | WPHA/WNT Endorsed | Human, Mice, Rat, Fish | 0.4 | KE:155 | Inadequate DNA repair |
| KE:1636 | Increase, Chromosomal aberrations | ||||||
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory system disease | Under Development | Human, Mouse, Rat | 0.2 | KE:1250 | Decrease, Lung function |
| AOP:313 | Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease | Immune system disease; Integumentary system disease; Musculoskeletal system disease | Under Development | Homo sapiens, Mus musculus | 0.2 | KE:1709 | Psoriatic skin disease |
| AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive system disease | - | 0.6 | KE:155 | Inadequate DNA repair | |
| KE:1365 | Increase, Apoptosis | ||||||
| KE:1757 | Reduce, Sperm count | ||||||
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.29 | KE:1846 | Thrombosis and Disseminated Intravascular Coagulation |
| KE:1869 | Diminished protective oxidative stress response | ||||||
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | 0.33 | KE:1603 | Chronic kidney disease | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory system disease | - | Homo sapiens | 0.25 | KE:1250 | Decrease, Lung function |
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | 0.6 | KE:1825 | Increase, Cell death | |
| KE:1250 | Decrease, Lung function | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.5 | KE:1250 | Decrease, Lung function | |
| KE:1262 | Apoptosis | ||||||
| AOP:422 | Binding of SARS-CoV-2 to ACE2 in enterocytes leads to intestinal barrier disruption | Gastrointestinal system disease | Under Development | 0.2 | KE:1931 | Intestinal barrier, disruption | |
| AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory system disease | - | Human | 0.17 | KE:1250 | Decrease, Lung function |
| AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory system disease | - | Human | 0.17 | KE:1250 | Decrease, Lung function |
| AOP:430 | Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation | Viral infectious disease | Under Development | Mink, Ferret, Cat, Dog, Syrian golden hamster, Rhesus macaque, Lowland gorilla, Crab eating macaque, African green monkeys, Humans, Hippopotamus amphibius, Bank vole, Lynx canadensis, Puma concolor, Panthera tigris jacksoni, Panthera uncia, Prionailurus viverrinus, Crocuta crocuta, Arctictis binturong, Odocoileus virginianus, American mink, Nasua nasua, Panthera leo, Sus scrofa, European rabbit, Castor fiber, Aonyx cinereus, Vulpes vulpes, Nyctereutes procyonoides, Tupaia belangeri, Bos taurus, Odocoileus hemionus, Peromyscus maniculatus bairdii, Cynopterus brachyotis, Common marmoset, Baboon | 0.2 | KE:1939 | Viral infection and host-to-host transmission, proliferated |
| AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic system disease; Cancer | - | Homo sapiens, Mus musculus | 0.27 | KE:1955 | Acute Myeloid Leukemia |
| KE:870 | Increase, Cell Proliferation | ||||||
| KE:155 | Inadequate DNA repair | ||||||
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | 0.25 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| KE:759 | Increased, Kidney Failure | ||||||
| KE:1365 | Increase, Apoptosis | ||||||
| AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural tube defect | - | 0.14 | KE:1561 | Neural tube defects | |
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:1583 | Sensory axonal peripheral neuropathy |
| KE:352 | N/A, Neurodegeneration | ||||||
| AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal system disease | Under Review | Zebrafish, Mouse, Human, Sebastiscus marmoratus, Salmo salar, Chicken | 0.17 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | Zebrafish, Mouse, Human, Chicken | 0.33 | KE:317 | Altered, Cardiovascular development/function |
| KE:947 | Increase, Early Life Stage Mortality | ||||||
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.33 | KE:2119 | Insulin resistance, increased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.25 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.22 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.12 | KE:341 | Impairment, Learning and memory |
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental disorder of mental health | - | 0.09 | KE:341 | Impairment, Learning and memory | |
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.38 | KE:2144 | Impaired insulin signaling | |
| KE:2119 | Insulin resistance, increased | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:191 | Neuronal dysfunction | ||||||
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:341 | Impairment, Learning and memory |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.57 | KE:1262 | Apoptosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:352 | N/A, Neurodegeneration | ||||||
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.25 | KE:2150 | Neurological disorder |
| AOP:519 | Cardiac ion channels blockade leading to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | Human and other cells in culture, Guinea pig, Rabbit | 0.25 | KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population |
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.4 | KE:2204 | Altered brain morphology |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.08 | KE:341 | Impairment, Learning and memory | |
| AOP:530 | Endocytotic lysosomal uptake leads to intestinal barrier disruption | Gastrointestinal system disease | - | 0.2 | KE:1931 | Intestinal barrier, disruption | |
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.17 | KE:341 | Impairment, Learning and memory | |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.5 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.22 | KE:1262 | Apoptosis |
| KE:341 | Impairment, Learning and memory | ||||||
| AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular system disease | - | Fish | 0.29 | KE:2237 | Decreased, Plasma sodium concentrations |
| KE:1535 | Heart failure | ||||||
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular system disease | - | Human, Mouse, Rat | 0.2 | KE:1535 | Heart failure |
| AOP:551 | Increased Muscarinic M2 Receptor leading to Arrhythmia | Symptom | - | Human, Mouse, Rat | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:552 | Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) | Cardiovascular system disease | - | Human, Rat, Mouse | 0.17 | KE:1535 | Heart failure |
| AOP:553 | Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure | Cardiovascular system disease | - | Human, Rodents, Dogs, Pigs, Insects, Fish | 0.25 | KE:1535 | Heart failure |
| AOP:554 | β-adrenergic receptor agonists leading to arrhythmias. | Symptom | - | Human and other cells in culture, Rodents, Macaca mulatta, Zebrafish, Gallus gallus | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:555 | Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Dogs, Rat, Guinea pig, Rabbits, Zebrafish | 0.2 | KE:1535 | Heart failure |
| AOP:556 | Decreased Na/K ATPase activity leading to heart failure | Cardiovascular system disease | - | 0.17 | KE:1535 | Heart failure | |
| AOP:558 | Phosphodiesterase inhibition leading to heart failure | Cardiovascular system disease | - | Human and other cells in culture, Rodents, Dog, Pig, Zebrafish | 0.17 | KE:1535 | Heart failure |
| AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | Human and other cells in culture, Rattus norvegicus, Dogs, Sus scrofa, Zebrafish, Insecta sp. BOLD:AAN5199 | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:560 | Inhibition of Funny current (If) leading to Arrhythmias | Symptom | - | Human and other cells in culture, Rodents, Dogs, Zebrafish | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:562 | HCN Channel Inhibition leading to Arrhythmias | Symptom | - | Human and other cells in culture, Dogs, Zebrafish, Rodents, Pigs | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
| AOP:572 | Imidacloprid-Induced BMP4 inhibition Leading to Neural Tube Closure Defects | Neural tube defect | - | 0.2 | KE:1561 | Neural tube defects | |
| AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory system disease | - | Rodents, Humans | 0.67 | KE:2316 | Increased, pulmonary edema |
| KE:1825 | Increase, Cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.25 | KE:486 | systemic inflammation leading to hepatic steatosis | |
| AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary system disease | - | Mus musculus, Rattus norvegicus | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| KE:793 | Increase, Urinary bladder calculi | ||||||
| AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal system disease | - | 0.25 | KE:1286 | Down Regulation, GSS and GSTs gene | |
| KE:1287 | Glutathione synthesis | ||||||
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.75 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| KE:1821 | Decrease, Cell proliferation | ||||||
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.33 | KE:1771 | Decrease, Adenosine triphosphate pool | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | Human | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal system disease | Under Review | Homo sapiens | 0.33 | KE:1753 | Chronic reactive oxygen species |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.4 | KE:1115 | Increase, Reactive oxygen species |
| KE:1769 | Increase, Body fluid overload | ||||||
| AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | Daphnia magna | 0.4 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | Daphnia magna, Paracyclopina nana | 0.4 | KE:1771 | Decrease, Adenosine triphosphate pool |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | Daphnia magna | 0.4 | KE:1365 | Increase, Apoptosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation | |
| KE:1771 | Decrease, Adenosine triphosphate pool | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | Fish, Mice | 0.67 | KE:1607 | Increase, Necrosis |
| KE:759 | Increased, Kidney Failure | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:926 | Oxidation, Glutathione (To be considered with MIE) | ||||||
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.3 | KE:155 | Inadequate DNA repair |
| KE:1669 | Increased, DNA damage and mutation | ||||||
| KE:1554 | Increase Chromosomal Aberrations | ||||||
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.3 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1993 | Increase, Pneumonia | ||||||
| KE:1250 | Decrease, Lung function | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal system disease | - | 0.15 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1931 | Intestinal barrier, disruption | ||||||
| AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal system disease | - | 0.15 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1931 | Intestinal barrier, disruption | ||||||
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.06 | KE:1115 | Increase, Reactive oxygen species |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.75 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
| KE:786 | Increase, Cytotoxicity (hepatocytes) | ||||||
| KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | ||||||
| AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.33 | KE:1817 | Apoptotic cell death | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.25 | KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1919 | Increased, Cardiac Dysregulation | ||||||
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.18 | KE:2001 | Cardiac hypertrophy | |
| KE:1929 | Increased incidence of cardiovascular morbidity and mortality in the general population | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.36 | KE:2034 | liver dysfunction | |
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.56 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| KE:1825 | Increase, Cell death | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:759 | Increased, Kidney Failure | ||||||
| KE:149 | Increase, Inflammation | ||||||
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.43 | KE:1869 | Diminished protective oxidative stress response |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.8 | KE:1513 | General Apoptosis |
| KE:885 | Increase, Cancer | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.8 | KE:1513 | General Apoptosis |
| KE:885 | Increase, Cancer | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1060 | Alteration, lipid metabolism |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.